第三代表皮生长因子受体酪氨酸激酶抑制剂在晚期非小细胞肺癌治疗中的挑战 - Suppr | 超能文献

The Challenges of Third-Generation EGFR Tyrosine Kinase Inhibitors in the Therapy of Advanced NSCLC.

作者信息

Wang Fen, Zhou Qing

机构信息

Department of Oncology, Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research, Cancer Institute, Peking University Shenzhen Hospital, Shenzhen-Peking University-Hong Kong University of Science and Technology Medical Center, Shenzhen, People's Republic of China; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China.

Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China; Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China.

出版信息

J Thorac Oncol. 2022 Apr;17(4):481-486. doi: 10.1016/j.jtho.2022.01.007.

DOI:10.1016/j.jtho.2022.01.007

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

The Challenges of Third-Generation EGFR Tyrosine Kinase Inhibitors in the Therapy of Advanced NSCLC.第三代表皮生长因子受体酪氨酸激酶抑制剂在晚期非小细胞肺癌治疗中的挑战

J Thorac Oncol. 2022 Apr;17(4):481-486. doi: 10.1016/j.jtho.2022.01.007.

2

And Still They Come Over Troubled Waters: Can Asia's Third-Generation EGFR Tyrosine Kinase Inhibitors (Furmonertinib, Aumolertinib, Rezivertinib, Limertinib, Befotertinib, SH-1028, and Lazertinib) Affect Global Treatment of EGFR+ NSCLC.尽管困难重重，它们仍纷至沓来：亚洲的第三代表皮生长因子受体酪氨酸激酶抑制剂（伏美替尼、奥莫替尼、瑞泽替尼、利美替尼、贝福替尼、SH-1028和拉泽替尼）能否影响表皮生长因子受体阳性非小细胞肺癌的全球治疗？

J Thorac Oncol. 2022 Oct;17(10):1144-1154. doi: 10.1016/j.jtho.2022.08.016.

3

Lazertinib: First Approval.拉泽替尼：首次批准。

Drugs. 2021 Jun;81(9):1107-1113. doi: 10.1007/s40265-021-01533-x.

4

Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study.在 EGFR 突变阳性的晚期非小细胞肺癌患者中使用 lazertinib：一项首次人体、开放标签、多中心、1-2 期剂量递增和剂量扩展部分的研究结果。

Lancet Oncol. 2019 Dec;20(12):1681-1690. doi: 10.1016/S1470-2045(19)30504-2. Epub 2019 Oct 3.

5

Third-generation EGFR-TKIs—a new hope for NSCLC.第三代表皮生长因子受体酪氨酸激酶抑制剂——非小细胞肺癌的新希望。

Lancet Respir Med. 2014 Jul;2(7):520. doi: 10.1016/s2213-2600(14)70095-5.

6

EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation.EGFR C797S作为拉泽替尼在伴有EGFR T790M突变的非小细胞肺癌中的耐药机制

Cancer Res Treat. 2020 Oct;52(4):1288-1290. doi: 10.4143/crt.2020.278. Epub 2020 Jun 22.

7

[Mechanisms of Resistance to the Third-generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer].[非小细胞肺癌对第三代表皮生长因子受体酪氨酸激酶抑制剂的耐药机制]

Zhongguo Fei Ai Za Zhi. 2018 Feb 20;21(2):110-115. doi: 10.3779/j.issn.1009-3419.2018.02.02.

8

Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial.分析第三代 EGFR 酪氨酸激酶抑制剂阿维替尼治疗 EGFR T790M 阳性非小细胞肺癌患者的耐药机制：来自 I 期临床试验的结果。

EBioMedicine. 2019 May;43:180-187. doi: 10.1016/j.ebiom.2019.04.030. Epub 2019 Apr 23.

9

Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors.对抗癌症耐药性：突变特异性 EGFR 抑制剂的机遇与挑战。

Drug Resist Updat. 2015 May;20:12-28. doi: 10.1016/j.drup.2015.05.002. Epub 2015 May 12.

10

Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors.表皮生长因子受体（EGFR）突变阳性非小细胞肺癌患者一线 EGFR 酪氨酸激酶抑制剂治疗后治疗模式的观察性研究。

Adv Ther. 2020 Feb;37(2):946-954. doi: 10.1007/s12325-020-01221-4. Epub 2020 Jan 18.

引用本文的文献

1

The advance of the third‑generation EGFR‑TKI in the treatment of non‑small cell lung cancer (Review).第三代 EGFR-TKI 在非小细胞肺癌治疗中的进展（综述）。

Oncol Rep. 2024 Jan;51(1). doi: 10.3892/or.2023.8675. Epub 2023 Dec 8.

2

Management of diarrhea induced by EGFR-TKIs in advanced lung adenocarcinoma.晚期肺腺癌中表皮生长因子受体酪氨酸激酶抑制剂所致腹泻的管理

Ther Adv Med Oncol. 2023 Aug 24;15:17588359231192396. doi: 10.1177/17588359231192396. eCollection 2023.

3

Lazertinib: on the Way to Its Throne.拉泽替尼：迈向王座之路。

Yonsei Med J. 2022 Sep;63(9):799-805. doi: 10.3349/ymj.2022.63.9.799.